A 4-year-old boy with drug-resistant epilepsy undergoes trio exome sequencing. A de novo missense variant in SCN2A is identified and classified as pathogenic. His seizures began at 2 months of age. Based on the age of onset, what is the predicted functional consequence of the variant and the most appropriate pharmacological strategy?